Drug discovery

Structure of ubiquitin
#Drug discovery #Protein ubiquitylation sites #Ubiquitin-proteasome #UbiSite

Ubiquigent obtains exclusive license for UbiSite technology

UK-based company Ubiquigent has signed an exclusive license with the University of Southern Denmark for its UbiSite technology. UbiSite will form a new component in Ubiquigent’s deubiquitylase (DUB) and ubiquitin-proteasome system (UPS) focused drug discovery platform. UbiSite technology uses an antibody specific to the C-terminal of ubiquitin for the capture… Read More

#Business & Investment #News

#Biotechnology #Drug discovery #Life sciences #Pharmacology

What’s interesting about Australian drug discovery? 

Australia’s drug discovery industry shows promise and innovation, as well as business opportunities. DDW’s Megan Thomas takes a look at some of the reasons why we should be keeping an interested eye on the developments coming out of this country.   The Sector Snapshot 2022: Expansion is continuous … Read More

#Exclusive Content #Market Reports #Trends & Analysis

#Biomarkers #Cancer research #Click chemistry #Covid-19 #Drug development #Drug discovery #Epstein-Barr virus #Monoclonal antibodies #mRNA #Oncology #Our Future Health #Pancreatic cancer

This week in drug discovery (24-28 October)

News round-up for 24-28 October by DDW Digital Content Editor Diana Spencer  Over the last seven days we’ve seen discoveries that could lead to new treatments for Covid-19, pancreatic cancer and Epstein-Barr virus, as well as the launch of the UK’s largest health research programme and the innovative application of… Read More

#News

Epstein-Barr Virus
#Drug development #Drug discovery #Epstein-Barr virus #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases

Experimental monoclonal antibodies block EBV infection

A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) have been shown to block infection when tested in human cells in a laboratory setting.  One of the experimental mAbs provided nearly complete protection against EBV infection and lymphoma when tested in… Read More

#News

#Animal models #Biology #Drug discovery #MPS technology #Podcast

Podcast: The role of animals in the future of drug discovery

This is the latest episode of the free DDW podcast, “The role of animals in the future of drug discovery”. It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW, narrated by DDW Multimedia Editor Megan Thomas. They are called “How an animal model… Read More

#News

#DNA technology #Drug discovery #Podcast #Recombinant DNA #Target identification #Target validation

Recombinant DNA technology and its impact on drug discovery: Podcast

The latest DDW Sitting Down With sponsored podcast features Yuning Chen, Senior R&D Manager at Sino Biological. Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and… Read More

#News

#DNA technology #Drug discovery #Podcast #Recombinant DNA #Sitting Down With #Target identification #Target validation

Recombinant DNA technology and its impact on modern drug discovery

The latest DDW Sitting Down With sponsored podcast features Yuning Chen, Senior R&D Manager at Sino Biological. Recombinant production is a field in which Sino Biological has extensive expertise – the company boasts several platforms to use recombinant DNA technology for the manufacturing of a variety of proteins and… Read More

#Podcasts

#cryo-microscopy #Drug discovery #Webinar

High resolution electron cryo-microscopy: From membrane proteins to diseases

Watch the webinar High resolution electron cryo-microscopy: From membrane proteins to diseases, supported by Thermo Fisher Scientific.  The webinar demonstrates how cryo-EM is impacting high resolution structure biology from membrane proteins to diseases including Alzheimer’s disease and cancer therapeutics by showing high-resolution structures of these… Read More

Webinar date:
Brought to you by Thermo Fisher Scientific
#Webinars

Protein
#Drug discovery #ELRIG #Events #Protein Science #Proteins

Event: Protein sciences in drug discovery

The 2022 Protein Science in Drug Discovery ELRIG meeting will be held at The Babraham Research Campus, Cambridge UK from 2-3 November 2022. The meeting will host leading scientists from industry and academia and will aim to focus on the application of emerging areas of Protein Science to the challenges of… Read More

#News

#Antibiotic resistance #Antibiotics #Contraception #Contraceptive pill #Covid-19 #Drug development #Drug discovery #Idiopathic pulmonary fibrosis #Respiratory syncytial virus

This week in drug discovery (17-21 October)

News round-up for 17-21 October by DDW Digital Content Editor Diana Spencer  Amid continued concern about antibiotic resistance, the headline news this week was the discovery of a new antibiotic that could be effective against some of the most treatment-resistant pathogens.   However, there was also… Read More

#News

Flow cytometry
#Antibodies #Diagnostics #Drug discovery #Flow Cytometry

Leveraging flow cytometry in drug discovery 

Listen to this article on the DDW podcast: Dr Miguel A Tam, and Dr Kenta Yamamoto, BioLegend, examine the evolution, trends and best practices for smooth and efficient workflows for flow cytometry.  Flow cytometry is a well-established analytical technique that has been supporting reliable diagnostics and… Read More

#News

Wear it Pink
#Breast cancer #Breast Cancer Now #Cancer research #Chemotherapy #Chemotherapy-resistance #Drug discovery #Oncology #Tumours

Five breakthroughs advancing breast cancer therapies

Not only is October Breast Cancer Awareness Month but October 21 is Wear it Pink 2022, Breast Cancer Now’s annual fundraising day. While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US1),… Read More

#Cancer Research #News #Trending News

Japanese flag
#Biopharmaceutical #Collaboration #Drug discovery #Healthcare #Investment #Life sciences #Market reporting #Start-ups

A review of Japan’s drug discovery landscape  

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research.   Japan continues to be one of the largest pharmaceutical markets in the world,… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #Trends & Analysis

#AI #Deep learning #Drug discovery #Investment #Machine learning

€30 million raised to advance AI enabled drug discovery pipeline 

Aqemia has raised €30 million in a Series A funding round to further support its mission to massively scale drug discovery through a first-in-class technological platform combining quantum-inspired physics and machine learning.  The financing was led by Eurazeo and Bpifrance through its Large Venture fund, with the… Read More

#Business & Investment #News

#Drug delivery #Drug development #Drug discovery #Mucoadhesive drug delivery

Unlocking the potential of mucoadhesive drug delivery

Listen to this article on the DDW Podcast: Ashley Rein, Global Market Manager for Topical Drug Delivery at Lubrizol Life Science Health (LLS Health), explains how by using mucoadhesive drug delivery, developers can bring novel drugs to market and maximise the efficacy of pre-existing APIs. … Read More

#Exclusive Content

Ukraine clinical research
#Clinical research #Clinical trials #Drug discovery #Russia #Ukraine

“Nothing scares us” – Ukraine’s clinical research sector begins fearless recovery

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko, Clinical Research Director at Medical Center Ok!Clinic+ to understand the impact… Read More

#Editor's Choice #Exclusive Content